Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure
Terminated
AstraZeneca
Phase 3
2003-07-01
Beta-blocker medications have been shown to improve heart function and prolong the lives of
patients with chronic heart failure (CHF). Some people with advanced CHF have difficulty
taking beta-blocker medications due to troublesome side effects, such as low blood pressure
and/or low heart rate, severe tiredness, dizziness, or shortness of breath. In other words,
they have difficulty tolerating beta-blocker medications. The purpose of this study is to
determine if enoximone can improve a patient's ability to tolerate a beta-blocker medication.
Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure
Terminated
Gilead Sciences
Phase 3
2003-07-01
Beta-blocker medications have been shown to improve heart function and prolong the lives of
patients with chronic heart failure (CHF). Some people with advanced CHF have difficulty
taking beta-blocker medications due to troublesome side effects, such as low blood pressure
and/or low heart rate, severe tiredness, dizziness, or shortness of breath. In other words,
they have difficulty tolerating beta-blocker medications. The purpose of this study is to
determine if enoximone can improve a patient's ability to tolerate a beta-blocker medication.
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
Terminated
GlaxoSmithKline
Phase 3
2005-07-01
This study was designed to determine whether COREG MR is more effective than TOPROL-XL in
reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood
pressure and microalbuminuria.
A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation.
Completed
AstraZeneca
Phase 4
2004-07-01
Mitral valve regurgitation (leakage of the mitral valve of the heart) is frequent and
currently there is no specific medical therapy. Mitral regurgitation is a slowly progressive
disease that frequently requires surgical treatment. This randomized clinical trial will use
Metoprolol, a common beta-blocker medication, to determine if medical treatment impacts
mitral valve disease progression.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
